ProCE Banner Activity

Phase III ENDURANCE: Carfilzomib/Len/Dex vs Bortezomib/Len/Dex in Newly Diagnosed Multiple Myeloma

Slideset Download
Conference Coverage
In standard- or intermediate-risk patients with newly diagnosed MM who were not intended for early ASCT, KRd did not improve PFS compared with VRd

Released: June 09, 2020

Expiration: June 08, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono